

Index

Note: Page numbers of article titles are in **boldface** type.

A

- AC133 antigen, in brain tumor cancer cells, 32–35
- Activity-based restoration therapy, for spinal cord injury, 153, 159–162
- Adrenoleukodystrophy, oligodendrocyte progenitor cell therapy for, 97
- Age factors, in spinal cord injury recovery, 144, 148
- Akt protein, in platelet-derived growth factor action, in gliomagenesis, 41
- Amantadine, for Parkinson's disease, 132
- American Spinal Injury Association impairment scale, 146–147
- Angiogenesis
 - in gliomagenesis, 46
 - platelet-derived growth factor in, 42
- Apoptosis
 - in radiation injury, 116
 - in spinal cord injury, 145
 - induction of, in gliomas, 76
- Astrocytes. *See also* Gliomas.
 - as niche cells, 83
 - growth of, from stem cells, 15–16
 - in neurogenesis, 83
- Astrocytic stem cells, **21–30**
 - characteristics of, 25, 27
 - early studies of, 22–24
 - family of, 24–26
 - in tumorigenesis, 27–28
- Astrocytomas, pathogenesis of, stem cells in, 27–28

B

- Baclofen, for spinal cord injury, 162
- Bmi 1 protein
 - in medulloblastoma, 62
 - in stem cell niches, 86

Bone marrow

- stem cells from
 - dopaminergic neuron generation from, 135
 - for gliomas, 77–78
- transplantation of, for lysosomal storage disorders, 6

Bone morphogenetic proteins, in stem cell niches, 85–86

Brain

- injury of, neurogenesis in, 48–49, **169–181**
- stem cells in. *See also* Neural stem cells.
 - in subventricular zone, **15–20**

Brain lipid-binding protein, in cancer stem cells, 34

- Brain tumors. *See also specific type, eg, Gliomas; Medulloblastomas.*
 - astrocytic stem cells in, 27–28
 - cancer stem cells in, **31–38**
 - embryonal, 59
 - platelet-derived growth factor involvement in, **39–58**

- Brain-derived neurotrophic factor (BDNF)
 - in brain ischemia, 185
 - in spinal cord injury, 161–162

C

- C17.2 stem cells, for cytosine deaminase delivery, 74–75
- Calbindin-D, in medulloblastoma, 63
- Canavan's disease, oligodendrocyte progenitor cell therapy for, 97, 99
- Cancer, brain. *See also* Gliomas; Medulloblastomas.
 - radiation therapy for, stem cell response to, **115–127**
- Cancer stem cell hypothesis, **31–38**
 - CD133 in, 31–35, 61–62, 64–65
 - cell origin in, 35–36, 49

Cancer stem cell hypothesis (*continued*)
 in gliomagenesis, 49–51
 in medulloblastoma pathogenesis, 64–66
 leukemia and, 32
 prospective identification of, 32–33
 research implications of, 36
 treatment implications of, 36

Carbidopa, for Parkinson's disease, 132

CD133 (prominin-1)
 in brain tumor cancer cells, 31–35
 in cerebellar development, 61
 in medulloblastoma, 62, 64–65

Central pattern generator, in spinal cord injury, 151–152

Cerebellum
 development of, 59–61
 medulloblastomas of. *See* Medulloblastomas.

Cerebral cortex, neurogenesis in, after traumatic brain injury, 178

Cerebral palsy, oligodendrocyte progenitor cell therapy for, 97–98

Ceroid lipofuscinoses, oligodendrocyte progenitor cell therapy for, 97

Chemokines and chemokine receptors
 in gliomagenesis, 47, 72
 in radiation injury, 121

Ciliary neurotrophic factor, in platelet-derived growth factor action, in gliomagenesis, 41

CNP protein, in neurogenesis, 24

Cognitive impairment, in radiation exposure, 115–116

Cortex, cerebral, neurogenesis in, after traumatic brain injury, 178

Cryptic Arg-Flu-Aso RDG protein, in gliomagenesis, 46

Culture
 of dopaminergic neurons, for Parkinson's disease, 134–137
 of stem cells, niche considerations in, 86–88

Cystatin C, in neural stem cell propagation, 84

Cytokines
 in spinal cord injury, 145
 stem-cell delivery of, 73–74

Cytosine deaminase, stem-cell delivery of, 74–75

D

Deep brain stimulation, for Parkinson's disease, 132

Delta-1 protein, in neural stem cell propagation, 84

Demyelinating diseases
 oligodendrocyte progenitor cell therapy for, **93–104**
 future of, 101–102
 in pediatric patients, 97–100
 in spinal cord injury, 101
 neonatal delivery of, 97–99
 optimal cellular vectors for, 94–97
 spinal cord injury as, 145

Dentate gyrus
 neurogenesis in, 47
 after traumatic brain injury, 170–174
 memory and, 106–107, 109
 stem cells in
 in niches, 81–88
 radiation response of, 118–123

DJ1 protein defects, in Parkinson's disease, 130

Dopaminergic neurons, in Parkinson's disease
 degeneration of, 129–132
 stem cell-derived, 133–137

Dyskinesia, in Parkinson's disease, 129, 132

E

Embryonal tumors, 59. *See also* Medulloblastomas.

Embryonic stem cells, **1–14**
 challenges in using, 7–8
 for central nervous system disorders, 2–3
 for demyelinating disorders, 101
 for in vivo organ generation, 9
 for lysosomal storage disorders, 6–7
 for organ transplantation, 9
 for Parkinson's disease, 134–137, 139
 for spinal cord injury, 152–159
 for transgenic mice generation, 1–2
 immune issues with, 9
 in utero transplantation of, 8–9
 potential uses of, 2–11
 versus neural stem cells, 8

Entacapone, for Parkinson's disease, 132

Ependymal cells, neurogenesis and, 22–23, 25–26

Ependymogial cells, in astrocyte family, 25–26

Ependymomas, cancer stem cells in, 34

Epidermal growth factor
 in brain ischemia, 185
 in gliomagenesis, 46
 in neural stem cell propagation, 83–84
 in stem cell migration, 72

Exercise, for spinal cord injury, 153, 159–162

External germinal layer
 in medulloblastoma, 62–64
 of cerebellum, 60

Extracellular matrix, in gliomagenesis, 44–47, 49

F

Fetus
 brain tissue from, transplantation of, for
 Parkinson's disease, 133
 neural stem cells of
 culture of, 87–88
 niches of, 81
 oligodendrocyte, 94–98
 transplantation of, for Parkinson's disease,
 136–137
 stem cell therapy for, 9–10

Fibroblast(s), in gliomagenesis, 44–47

Fibroblast growth factor
 in brain ischemia, 186
 in dopaminergic neuron generation, 134–135
 in neural stem cell propagation, 83–84

Forkhead transcription factors,
 in platelet-derived growth factor action,
 in gliomagenesis, 41

Functional electrical stimulation, for spinal cord
 injury, 160–162

Functional Independence Measure, in spinal cord
 injury, 148–149

G

Gait central pattern generator, in spinal cord
 injury, 151–152

Galactocerebrosidase, stem-cell delivery of, 74

Gangliosidoses, oligodendrocyte progenitor cell
 therapy for, 97

Gli 1 transcription factor, in stem cell
 maintenance, 85

Glial cell line–derived neurotrophic factor
 in brain ischemia, 185
 in dopaminergic neuron generation, 134–135

Glial fibrillary acidic protein expression
 in astrocytic family, 24–25
 in spinal cord injury, 145
 regulation of, 86

Glial progenitor cell therapy. *See* Oligodendrocyte
 progenitor cell therapy.

Glioblastomas, cancer stem cells in, 34

Gliomas
 microenvironment of, 44–47
 pathogenesis of
 astrocytic stem cells in, 27–28
 platelet-derived growth factor in, **39–58**
 stem cell therapy for, **71–80**
 challenges in, 78–79
 drug delivery in, 73–76
 glioma-tropic migration in, 72
 inherent antitumor activity of, 76–77
 problems with, 77–78
 tumor-homing capacity of, 71–72

Glutamate toxicity, in spinal cord injury, 144–145

Graft-versus-host disease, 157–158

Granule cell precursors, in external germinal
 layer, 60

Growth factors. *See specific growth factors.*

H

Hedgehog protein
 in dopaminergic neuron generation, 134, 136
 in medulloblastoma, 61–64, 66
 in stem cell maintenance, 84–85

Hematopoietic stem cells
 leukemia development from, 32
 versus neural stem cells, 22, 27

Hemispherectomy, functional return after, 152

Herpes simplex virus, oncolytic, stem-cell delivery
 of, 75–76

Hes 1 protein, in medulloblastoma, 62

Hippocampus, neurogenesis in
 after traumatic brain injury, 170–174
 astrocytic stem cells in, **21–30**
 memory and, **105–113**

Homologous recombination, in stem cell
 generation, 1–2

Human leukocyte antigens, of stem cells, 9

Hypoxia, in spinal cord injury, 145

I

-
- Immune response, to stem cells, 9
 - in Parkinson's disease treatment, 138
 - in spinal cord injury, 157–159
 - Injury
 - radiation. *See* Radiation response.
 - spinal cord. *See* Spinal cord injury.
 - Insulin-like growth factor-I, in brain ischemia, 186–187
 - Integrins, in brain development, 44–45
 - Interleukins, stem-cell delivery of, 74
 - International Center for Spinal Cord Injury, neurorestoration program of, 160–161
 - Ionizing radiation response. *See* Radiation response.
 - Ischemia
 - in spinal cord injury, 145
 - neurogenesis in, **183–190**
 - brain-derived neurotrophic factor in, 185
 - epidermal growth factor in, 185
 - fibroblast growth factor in, 186
 - glial cell line–derived neurotrophic factor in, 185
 - insulin-like growth factor-I in, 186–187
 - platelet-derived growth factor in, 187–188

J

-
- Jagged-1 protein, in neural stem cell propagation, 84
 - Jak family kinases, in platelet-derived growth factor action, in gliomagenesis, 41

K

-
- Krabbe's disease, oligodendrocyte progenitor cell therapy for, 97, 99

L

-
- Learning, neurogenesis in, 106–110
 - Leukemia, cancer cell hypothesis and, 32
 - Leukemia inhibitory factor, in stem cell niches, 86
 - Leukodystrophies, oligodendrocyte progenitor cell therapy for
 - challenges in, 99–100
 - future of, 101–102
 - neonatal delivery of, 97–99
 - optimal cellular vectors for, 94–97

- Levodopa, for Parkinson's disease, 130, 132
- Lewy bodies, in Parkinson's disease, 129–130
- LRRK2 protein defects, in Parkinson's disease, 130
- Lysosomal storage disorders
 - oligodendrocyte progenitor cell therapy for, 97, 99
 - stem cell therapy for, 6–7

M

-
- Macrophages, growth factors in,
 - in gliomagenesis, 46–47
 - Magnetic resonance imaging, in spinal cord injury, 148–150
 - Major histocompatibility complex antigens, matching of, in stem cell therapy, 158
 - Matrix metalloproteinases, in gliomagenesis, 46
 - Medulloblastomas, **59–70**
 - cancer stem cells in, 34, 64–66
 - neural stem cells and, 61–64
 - origin of, 62–64
 - radioresistant cells in, 65
 - spread of, 60–61
 - versus normal cerebellar development, 59–61
 - Memory, **105–113**
 - components of, 105
 - neurogenesis in
 - learning and, 106–110
 - processes of, 106
 - regulation of, 106–107
 - Metachromic leukodystrophy, oligodendrocyte progenitor cell therapy for, 97, 99
 - Mitochondrial dysfunction, in Parkinson's disease, 130
 - Mitogen-activated protein kinase,
 - in platelet-derived growth factor action, in gliomagenesis, 41
 - Mitoxantrone, for multiple sclerosis, 100
 - Monocyte chemoattractant protein, in radiation injury, 121
 - Motor fluctuations, in Parkinson's disease, 132
 - Multiple sclerosis, oligodendrocyte progenitor cell therapy for, 100–101
 - Musashi, in medulloblastoma, 62

N

Natalizumab, for multiple sclerosis, 100

Neonates, demyelinating diseases in,
oligodendrocyte progenitor cell therapy for,
97–99

Nestin

in gliomagenesis, 50
in medulloblastoma, 62

Neural stem cells

astrocytic, **21–30**
cancer. *See* Cancer stem cell hypothesis.
characteristics of, 25, 27, 72
culture of, niche considerations in, 86–88
differentiation of, 3
for brain tumor therapy, **71–80**
for cancer, **71–80**
for Parkinson's disease, **129–142**
glial progenitor-based, for demyelinating
diseases, **93–104**
in brain tumors, **31–38**
embryonal, **59–70**
gliomas, **71–80**
identification of, **31–38**
medulloblastomas, **59–70**
platelet-derived growth factor and,
39–58
in cerebellar development, 59–61
in hippocampal memory function, **105–113**
in neurogenesis. *See* Neurogenesis.
in subventricular zone, **15–20**, 81–88
migration of, 72
niches for, **81–92**
astrocytes in, 83, 86
bone morphogenetic proteins in, 85–86
catalog of, 86
cell-intrinsic factors and, 86
clinical utility of, 86–88
concept of, 81
epidermal growth factor in, 83–84
fibroblast growth factor in, 83–84
leukemia inhibitory factor in, 86
notch signaling in, 84
overview of, 81–83
sonic hedgehog in, 84–85
Wnt signaling in, 84
radiation response of, **115–127**
versus embryonic stem cells, 8
versus hematopoietic stem cells, 27

Neuroblasts

generation of, for Parkinson's disease, 134
proliferative nature of, 23–24

Neuroectodermal cells, generation of, for
Parkinson's disease, 134

Neurogenesis-1, in stem cell niches, 85

Neurogenesis

after traumatic brain injury
cortical, 178
hippocampal, 170–174
subventricular zone, 174–178
treatment of, 178
astrocytic stem cells in, **21–30**, 83
endogenous precursors in, 88
growth factors in
in ischemia, 184–188
in normal situations, 183–184
in different species, 106
in gliomas, 27–28, 47–49
in ischemia, **183–190**
in memory function, **105–113**
learning and, 106–110
processes of, 106
regulation of, 106–107
radiation effects on, **115–127**

Neurogenin-1 transcription factor, 86

Neurons, growth of, from stem cells, 15–16

Neuroprotection, for Parkinson's disease,
132–133

Neurospheres

generation of
for Parkinson's disease, 134
from astrocytic stem cells, 24
from ependymal cells, 23
subventricular zone, 15–16

Niches, for neural stem cells, **81–92**

Noggin protein, in stem cell niches, 85

Notch proteins

in medulloblastoma, 61–62
in neural stem cell propagation, 84

Nurr-1, dopaminergic neurons expressing, 135

O

Olfactory bulb, neurogenesis in, 47

Oligodendrocyte(s)

destruction of, in spinal cord injury, 145
development of, platelet-derived growth factor
in, 42
growth of, from stem cells, 15–16
precursors of, proliferative nature of, 24

Oligodendrocyte progenitor cell therapy, for demyelinating diseases, **93–104**
 future of, 101–102
 in pediatric patients, 97–100
 in spinal cord injury, 101
 neonatal delivery of, 97–99
 optimal cellular vectors for, 94–97

Organ replacement, stem cells for, 10

Organic acidurias, oligodendrocyte progenitor cell therapy for, 97

Oxidative stress
 in radiation injury, 122–123
 in spinal cord injury, 145

P

p75 protein, 63

Parkin protein defects, in Parkinson's disease, 130

Parkinson's disease, **129–142**
 genetics of, 129–130
 medical treatment of, 130, 132
 neuroprotection in, 132–133
 neurosurgical treatment of, 132
 pathophysiology of, 129–131
 prognostic factors in, 129
 stem cell therapy for, 4–5, 133–140
 animal models of, 135–137
 bone marrow, 135
 dopaminergic neuron generation, 133–137
 embryonic, 134
 future of, 138–140
 neural, 134–135
 protein delivery in, 137–138
 tissue transplantation, 133
 umbilical, 135
 symptoms of, 129

Partial body weight-supported walking, in spinal cord injury, 152, 161

PDGF. *See* Platelet-derived growth factor.

Pediatric patients, demyelinating diseases in, oligodendrocyte progenitor cell therapy for, 97–100

Pelizaeus-Merzbacher disease, oligodendrocyte progenitor cell therapy for, 97

Periventricular leukomalacia, oligodendrocyte progenitor cell therapy for, 97

Phosphatidylinositol 3-kinase, in platelet-derived growth factor action, in gliomagenesis, 41

Phospholipase C, in platelet-derived growth factor action, in gliomagenesis, 41

PINK1 protein defects, in Parkinson's disease, 130

Platelet-derived growth factor
 in brain ischemia, 187–188
 in gliomagenesis, **39–58**
 causal relations in, 42–44
 family of, 39–40
 first identification of, 39
 ligands of, 39–41
 receptors for, 41
 signal transduction pathway in, 41
 structures of, 39–40
 theories of, 49–51
 tropism in, 47–49
 tumor recruitment in, 44–49
 versus normal development, 42
 in stem cell migration, 72

Primitive neuroectodermal tumors, origin of, 61–62

Proapoptotic proteins, stem-cell delivery of, 76

Prodrugs, stem-cell delivery of, 74–75

Prominin-1 (CD133)
 in brain tumor cancer cells, 31–35
 in cerebellar development, 61
 in medulloblastoma, 62, 64–65

Prominin-2, in brain tumor cancer cells, 33

Protein kinase C, in platelet-derived growth factor action, in gliomagenesis, 41

R

Radiation response, of neural stem cells, **115–127**
 in dentate subgranular zone, 118–123
 in subventricular zone, 116–118

Rasagiline, for Parkinson's disease, 132–133

Reactive oxygen species
 in radiation injury, 122–123
 in spinal cord injury, 145

Rehabilitation, for spinal cord injury, 153, 159–162

Rejection, of stem cells, 9

Respiratory chain protein complex dysfunction, in Parkinson's disease, 130

Rostral migratory stream, neurogenesis in, 21, 23, 47

S

-
- Scar formation, in spinal cord injury, 145
- Scatter factor/hepatocyte growth factor, in gliomagenesis, 45–46
- SH2 domain, in platelet-derived growth factor action, in gliomagenesis, 41
- SHH (sonic hedgehog) protein
in dopaminergic neuron generation, 134, 136
in medulloblastoma, 61–64, 66
in stem cell maintenance, 84–85
- Sly's disease, oligodendrocyte progenitor cell therapy for, 99
- Smoothed protein, in stem cell maintenance, 85
- Sonic hedgehog protein
in dopaminergic neuron generation, 134, 136
in medulloblastoma, 61–64, 66
in stem cell maintenance, 84–85
- Spastic paraplegia, oligodendrocyte progenitor cell therapy for, 97
- Spinal cord injury, **143–168**
clinical features of, 146
functional impairment scale for, 146–147
imaging in, 148–150
pathophysiology of, 144–147
phases of, 144–147
prognosis for, 147
repair of, 150–163
 central pattern generator and, 151–152
 embryonic stem cells for, 5–6, 152–159
 functional recovery and, 151–152
 oligodendrocyte progenitor cell therapy for, 101
 rehabilitation with, 159–162
 spontaneous, 150–151
 secondary, 144–145
- Src family kinases, in platelet-derived growth factor action, in gliomagenesis, 41
- Stem cell(s), **1–14**
cancer. *See* Cancer stem cell hypothesis.
challenges in using, 7–8
characteristics of, 72
embryonic. *See* Embryonic stem cells.
for central nervous system disorders, 2–3
for in vivo organ generation, 9
for lysosomal storage disorders, 6–7
for organ transplantation, 9
for Parkinson's disease. *See* Parkinson's disease.
for spinal cord injury. *See* Spinal cord injury.
for transgenic mice generation, 1–2
hematopoietic
 leukemia development from, 32
 versus neural stem cells, 22, 27
human leukocyte antigen matching of, 9
immune issues with, 9
in utero transplantation of, 8–9
neural. *See* Neural stem cells.
potential uses of, 3–11
rodent versus human, 8
transplantation of. *See* Transplantation.
types of, 71–72
- Stem cell factor, in stem cell migration, 72
- Stroke, neurogenesis in, growth factors in, 183–188
- Subependymal zone, neurogenesis in, 21–25
- Subgerminal zone, neurogenesis in, 47
- Subgranular zone
neurogenesis in, 21, 24
 after traumatic brain injury, 170–174
 memory and, 106
stem cells in
 niches in, 81–88
 radiation response of, 118–123
- Subthalamic nucleus, electrical stimulation of, for Parkinson's disease, 132
- Subventricular zone
neurogenesis in, 47–49
 after traumatic brain injury, 174–178
 memory and, 106
radiation response of, 116–118
stem cells in, **15–20**, 81–88
- α -Synuclein defects, in Parkinson's disease, 129–130
-
- T**
- Tenascin, in tumorigenesis, 27–28
- TLX transcriptional regulator, 86
- TNF-related apoptosis-inducing ligand (TRAIL), for gliomas, 76
- Transforming growth factor- β
in dopaminergic neuron generation, 134
in gliomagenesis, 46
- Transit-amplifying progenitor cells, 47
- Transplantation
bone marrow
 for gliomas, 77–78
 for lysosomal storage disorders, 6

Transplantation (*continued*)

- fetal brain tissue, for Parkinson's disease, 133
- rejection in, 157–158
- stem cell, for organ replacement, 10

Traumatic brain injury, **169–181**

- neurogenesis after
 - cortical, 178
 - hippocampal, 170–174
 - subventricular zone, 174–178
 - treatment of, 178
- neuronal loss in, 169–170

Tumor(s), brain. *See* Brain tumors.

Tumor necrosis factor, stem-cell delivery of, 76

Tumor-derived progenitors, in pediatric tumors, 34

Type A/B/C neuroblasts, proliferative nature of, 23–24

U

Umbilical cord stem cells, dopaminergic neuron generation from, 135

Urokinase plasminogen activator, in gliomagenesis, 46

VVanishing white matter disease,

- oligodendrocyte progenitor cell therapy for, 97

Ventricular zone germinal neuroepithelium

- cerebellar development from, 59
- in medulloblastoma, 62–63

Viral vectors, oncolytic, stem-cell delivery of, 75–76

W

Walking, partial body weight-supported, in spinal cord injury, 152, 161

Wechsler-Reya cells, in cerebellar development, 61

White matter, vanishing,

- oligodendrocyte progenitor cell therapy for, 97

Wnt pathway

- in medulloblastoma, 61–63
- in neural stem cell propagation, 84